Perseus Proteomics Inc.
Basic information
- Head office
- 3rd Floor, A.i.Nihombashi EAST, 30-1 Nihonbashi-Hakozakicho, Chuo-ku, Tokyo 103-0015, Japan
- Chief executive
- Takuya Yokokawa
- Capital
- 751,000,000 (7 100 million)
- Employees (non-consolidated)
- 35 people
- Employees (consolidated)
- 34 people
- Start date
- 2001-02-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| 富士フイルム株式会社 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
October 2002: A number of anti-nuclear receptor monoclonal antibodies are released as research reagents.![]()
April 2003: Participated in the Nanobiotechnology Project for Protein Interaction Analysis of the New Energy and Industrial Technology Development Organization (NEDO)![]()
April 2003: The company joins the “Protein Interaction Analysis Nano-biochip Project” sponsored by NEDO.![]()
Participated in the New Energy and Industrial Technology Development Organization (NEDO) “Protein Interaction Analysis Nanobiochip Project”![]()
The company joins the “Protein Interaction Analysis Nano-biochip Project” sponsored by the New Energy and Industrial Technology Development Organization (NEDO) of the Ministry of Economy, Trade and Industry.![]()
August 2004: Signed a sales agency agreement with R&D Systems, Inc. for sales of research reagents in the United States, and began sales worldwide![]()
August 2004: The company signs a distributorship agreement with R&D Systems Inc. for the distribution of research reagents in the US and initiates global sales.![]()
Entered into a distributor agreement with R&D Systems, Inc. for the sale of research reagents and began sales worldwide![]()
The company signs a distributorship agreement with R&D Systems Inc. for the distribution of its research reagents in the United States and initiates global sales.![]()
August 2004: Entered into a distributorship agreement with R&D Systems Inc. for the sale of research reagents and began sales worldwide.![]()
September 2006: Signed an agreement with Chugai Pharmaceutical Co., Ltd. concerning the transfer of rights to obtain patents and other rights relating to the anti-glypican 3 antibody “anti-liver cancer antibody (PPMX-T001)” (agreement expired in June 2022)![]()
September 2006: The company signs an agreement with Chugai Pharmaceutical for the transfer of rights for the therapeutic use of the anti-glypican 3 antibody.![]()
Entered into an agreement with Chugai Pharmaceutical Co., Ltd. to transfer rights, including the right to obtain patents, relating to a glypican-3 antibody (PPMX-T001)![]()
The company signs an agreement with Chugai Pharmaceutical Co., Ltd. for the transfer of right for the therapeutic use of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001).”![]()
September 2006: Entered into an agreement with Chugai Pharmaceutical Co., Ltd. to transfer rights, including the right to obtain patents, relating to a glypican 3 antibody (PPMX-T001).![]()
November 2008: Phase I clinical trial of the anti-glypican 3 antibody “liver cancer therapeutic” began in the United States (PPMX-T001)![]()
November 2008: A phase I clinical trial of the anti-glypican 3 antibody begins in the United States.![]()
A phase I clinical trial of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001)” begins in the United States.![]()
January 2009: Fujifilm Corporation increases its capital in Perseus Proteomics by acquiring 76.68% of shares, becoming the parent company.![]()
FUJIFILM Corporation became the parent company by acquiring 76.68% of the Company’s shares through a third-party allotment![]()
Through shareholder allocation, FUJIFILM Corporation increases its capital in Perseus Proteomics by acquiring 76.68% of the issued shares to become the parent company.![]()
January 2009: FUJIFILM Corporation acquired 76.68% of the Company's shares through a third-party allotment and became its parent company.![]()
January 2011: Licensed the radiolabeled antibody anticancer drug (PPMX-T002) to FUJIFILM Corporation![]()
A radioisotope (RI)-labeled antibody (PPMX-T002), an anticancer drug, is licensed to FUJIFILM Corporation.![]()
January 2011: Licensed a radioisotope (Note 2)-labeled cadherin 3 antibody to FUJIFILM Corporation (PPMX-T002).![]()
December 2014: A treatment for adult T-cell leukemia using an anti-transferrin receptor antibody (PPMX-T003) was selected as a project under the Practical Application Challenge Type (Drug Discovery and Development) of the Japan Science and Technology Agency (JST) Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP)![]()
December 2014: A drug based on an anti-transferrin receptor antibody (PPMX-T003) is selected for practical application development under JST's A-STEP program.![]()
The transferrin receptor antibody was selected for a project under the Practical Application Challenge Type (Drug Development) of the Japan Science and Technology Agency (JST)’s Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) (PPMX-T003)![]()
A drug for the treatment of adult T-cell leukemia based on an anti-transferrin receptor antibody (PPMX-T003) is selected by the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) program of the Japan Science and Technology Agency (JST) for the practical application development (drug development) division.![]()
December 2014: The transferrin receptor antibody was selected for the drug development project under the Practical Application Challenge Type (Drug Development) of the Japan Science and Technology Agency (JST)'s Adaptable and Seamless Technology Transfer Program through Target-driven R&D (PPMX-T003).![]()
September 2015: Licensed the drug-conjugated cadherin 3 antibody to FUJIFILM Corporation (PPMX-T004).![]()
January 2016: A Phase I trial in the United States began for PPMX-T002, an anticancer drug consisting of a radioisotope (RI)-labeled antibody drug.![]()
January 2016: A phase I clinical trial of the radioisotope-labeled antibody (PPMX-T002) begins in the United States.![]()
Phase I clinical trial of a radioisotope-labeled cadherin-3 antibody began in the United States (PPMX-T002)![]()
A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in the United States.![]()
January 2016: A Phase I trial of the radioisotope-labeled cadherin 3 antibody began in the United States (PPMX-T002).![]()
March 2018: FUJIFILM Corporation's ownership percentage in the Company decreased following a shareholder allotment of new shares, and it became an "other affiliated company" of the Company.![]()
March 2018: Fujifilm reduces its shareholding percentage to 48.62% and becomes an 'other associated company'.![]()
FUJIFILM Corporation’s shareholding in the Company fell to 48.62% through a third-party allotment, making it an other affiliated company of the Company![]()
After allocation of new shares to a third party, FUJIFILM Corporation reduces its percentage of shares of the Company to 48.62% and becomes an 'other associated company'.![]()
March 2018: Through a third-party allotment of shares, FUJIFILM Corporation's ownership stake in the Company reached 48.62%, making it an affiliate of the Company.![]()
January 2019: Opened the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, to maintain and advance phage display technology and promote research and development of antibody drugs.![]()
Opened the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, to maintain and develop phage display technology and promote research and development of antibody drugs![]()
The company opens the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, for the maintenance and development of phage display technologies and the promotion of research and development of antibody drugs.![]()
November 2019: The Company began a Phase I trial in Japan of an anticancer drug using an anti-transferrin receptor antibody (PPMX-T003).![]()
November 2019: A phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) begins in Japan.![]()
Phase I clinical trial in Japan of the transferrin receptor antibody for polycythemia vera, the Company’s first in-house clinical trial, began (PPMX-T003)![]()
A phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) as an anticancer drug begins in Japan.![]()
November 2019: A Phase I trial in patients with polycythemia vera of the transferrin receptor antibody, the Company's first company-sponsored clinical trial, began in Japan (PPMX-T003).![]()
April 2020: A Phase I trial in Japan began for PPMX-T002, an anticancer drug consisting of a radioisotope (RI)-labeled antibody drug.![]()
April 2020: A phase I clinical trial of the radioisotope-labeled antibody (PPMX-T002) begins in Japan.![]()
Phase I clinical trial in Japan of an anticancer drug using a radioisotope-labeled cadherin-3 antibody began (PPMX-T002)![]()
A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in Japan.![]()
April 2020: A Phase I trial in Japan began for the anticancer drug using a radioisotope-labeled cadherin 3 antibody (PPMX-T002).![]()
March 2022: Research and development of PPMX-T003 for aggressive NK-cell leukemia was selected as a project under the Drug Discovery Support Promotion Program and the Pre-Practical-Application Support Program for Orphan Drug Designation of the Japan Agency for Medical Research and Development (AMED).![]()
March 2022: Terminated the license agreements with FUJIFILM Corporation for PPMX-T002 and PPMX-T004.![]()
March 2022: Research project on ANKL (PPMX-T003) is selected under the AMED Drug Discovery Promotion Program.![]()
March 2022: License agreement for PPMX-T002 and license & knowhow agreement for PPMX-T004 between Fujifilm are terminated.![]()
Research and development targeting aggressive natural killer-cell leukemia (ANKL) was selected as a project under the FY2022 Drug Discovery Support Promotion Program’s Practical Application Support Program for Drugs for Rare Diseases Prior to Designation, administered by the Japan Agency for Medical Research and Development (AMED) (PPMX-T003)![]()
Research and development project on ANKL (PPMX-T003) is selected as a project under the AMED Drug Discovery Promotion Program and Pre-designation Support Program for Orphan Drugs.![]()
License Agreement for PPMX-T002 and License & Knowhow Agreement for PPMX-T004 between FUJIFILM are terminated.![]()
March 2022: Research and development targeting aggressive NK-cell leukemia (ANKL) was selected for the FY2022 project under the Drug Discovery Support Promotion Program's Pre-designation Practical Application Support Program for Orphan Drugs of the Japan Agency for Medical Research and Development (AMED) (PPMX-T003).![]()
April 2022: Transferred from the Mothers market to the Growth market following the Tokyo Stock Exchange's restructuring of its market segments.![]()
April 2022: The listed market transitions from Mother Market to Growth Market due to market segmentation restructuring.![]()
Following the Tokyo Stock Exchange's review of its market segments, the company moved from the Mothers market to the Growth market.![]()
The listed market transitions from Mother Market to Growth Market, TSE due to market segmentation restructuring of TSE.![]()
September 2022: Fujifilm Corporation's shareholding percentage reduces to 16.48%, no longer considered 'other associated company'.![]()
FUJIFILM Corporation is no longer "other associated company" due to reduction of its percentage of shares of the Company to 16.48%.![]()
March 2023: The clinical trial notification for a physician-initiated Phase I/II trial of PPMX-T003 for aggressive NK-cell leukemia (ANKL) was approved.![]()
March 2023: Clinical Trial Notification of Investigator-led Phase I/II Clinical Trial for ANKL (PPMX-T003) is submitted and approved.![]()
A clinical trial notification was submitted and approved for a physician-initiated Phase I/II trial targeting ANKL (PPMX-T003).![]()
Clinical Trial Notification of Investigator-led Phase I/II Clinical Trial for ANKL is submitted and approved.(PPMX-T003).![]()
March 2023: A clinical trial notification was submitted and approved for a physician-initiated Phase I/II trial targeting ANKL (PPMX-T003).![]()
February 2025: Research and development for ANKL was selected as a project under AMED's FY2025 Drug Discovery Support Promotion Program and Pre-Practical-Application Support Program for Orphan Drug Designation (PPMX-T003).![]()
February 2025: Research project on ANKL (PPMX-T003) is selected under the AMED Drug Discovery Promotion Program for FY2025.![]()
Research and development targeting ANKL was selected as a project under AMED's FY2025 Drug Discovery Support Promotion Program and Pre-Designation Support Program for Practical Application of Orphan Drugs (PPMX-T003).![]()
Research and development project on ANKL is selected as a project under the AMED Drug Discovery Promotion Program and Pre-designation Support Program for Orphan Drugs for FY2025 (PPMX-T003).![]()
The company began offering antibody research support for antibody screening and production using a VHH antibody library.![]()
News
There is no news.
Public records
National Tax Agency basic information1013201011111
- Trade name
- 株式会社ペルセウスプロテオミクス
- Trade name (kana)
- ペルセウスプロテオミクス
- Name in English
- Corporation type
- 301
- Address
- 〒103-0015 東京都中央区日本橋箱崎町30番1号
- Postal code
- 1030015
- Prefecture code
- 13
- City code
- 102
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2023-07-28
- Change date
- 2023-07-24
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 1405536
METI gBizINFO1013201011111
- Corporate number
- 1013201011111
- Trade name
- 株式会社ペルセウスプロテオミクス
- Trade name (kana)
- ペルセウスプロテオミクス
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都中央区日本橋箱崎町30番1号
- Postal code
- 1030015
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 中央区
- City code
- 102
- Street address
- 日本橋箱崎町30番1号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- 代表取締役社長執行役員 横川 拓哉
- Capital
- 751161000
- Employees
- 17
- Employees (male)
- 6
- Employees (female)
- 11
- Business summary
- 創薬、研究開発
- Website URL
- https://www.ppmx.com/
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2023-07-28
- Key information
- 1013201011111